Source comparison
Is CJC-1295 No DAC Safe Long Term Use: Comparison Table
| Compound | Half-Life | Dosing Frequency | Longest Published Human Study | Known Long-Term Risks | Receptor Desensitization Evidence | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 no DAC (modified GRF 1-29) | ~30 minutes | 1–3× daily | 90 days (JCEM 2004)
This comparison does not assign a generated winner or score.
- | Compound | Half-Life | Dosing Frequency | Longest Published Human Study | Known Long-Term Risks | Receptor Desensitization Evidence | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 no DAC (modified GRF 1-29) | ~30 minutes | 1–3× daily | 90 days (JCEM 2004) | Unknown beyond 6 months; theoretical pituitary feedback alteration | No human data; in vitro studies show ligand-induced downregulation | Use in 8–12 week cycles with washout periods until >6-month safety data exists || CJC-1295 with DAC | 6–8 days | 1–2× weekly | Case series to 6 months (no peer review) | Elevated risk of GH/IGF-1 supraphysiological levels; reported injection-site nodules | Likely but unstudied in humans | Avoid for continuous use. DAC persistence creates cumulative exposure risk || Tesamorelin (Egrifta) | 26–38 minutes | 1× daily | 26 weeks (HIV lipodystrophy FDA trial) | Glucose intolerance in 8% of subjects; arthralgia; fluid retention | No desensitization observed at 26 weeks | FDA-approved for specific in